Literature DB >> 24762076

Immunotherapeutic approaches for the treatment of eosinophilic esophagitis.

Antonella Cianferoni1, Jonathan M Spergel.   

Abstract

Eosinophilic esophagitis (EoE) is a clinical pathologic disease characterized by symptoms of esophageal dysfunction and eosinophilia of the esophagus. When the diagnosis is confirmed, it is important to treat the eosinophilic inflammation not only to control the presenting symptoms, but also to prevent acute and chronic complications. The pathogenesis of EoE is most likely a mixed IgE and non-IgE food-mediated reaction, where Th2 cytokines drive esophageal eosinophilia as in other atopic diseases. Hence, it is not surprising that therapy is based on inflammation control, with steroids (oral or topical) and/or food antigen avoidance. However, these treatment options are not specific, reduce the quality of life of patients and have significant side effects, therefore, there is an ongoing effort to design more specific immunotherapies. In this review, we review standard and immunotherapeutic options for EoE treatment, such as anti-IL-5, anti-TNFα, anti-IgE, anti-CRTH, oral allergy desensitization and environmental immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24762076      PMCID: PMC4697927          DOI: 10.2217/imt.14.3

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  92 in total

1.  Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response.

Authors:  A Straumann; M Bauer; B Fischer; K Blaser; H U Simon
Journal:  J Allergy Clin Immunol       Date:  2001-12       Impact factor: 10.793

2.  Eosinophilic esophagitis.

Authors:  Richard J Noel; Philip E Putnam; Marc E Rothenberg
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

3.  Enterocyte expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking.

Authors:  Anil Mishra; Simon P Hogan; Eric B Brandt; Norbert Wagner; Michael W Crossman; Paul S Foster; Marc E Rothenberg
Journal:  J Biol Chem       Date:  2001-11-30       Impact factor: 5.157

4.  Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate.

Authors:  Jonathan E Teitelbaum; Victor L Fox; Frank J Twarog; Samuel Nurko; Don Antonioli; Gerald Gleich; Kamran Badizadegan; Glenn T Furuta
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

5.  IL-5 promotes eosinophil trafficking to the esophagus.

Authors:  Anil Mishra; Simon P Hogan; Eric B Brandt; Marc E Rothenberg
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

6.  Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism.

Authors:  Anil Mishra; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

7.  Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula.

Authors:  K J Kelly; A J Lazenby; P C Rowe; J H Yardley; J A Perman; H A Sampson
Journal:  Gastroenterology       Date:  1995-11       Impact factor: 22.682

8.  Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.

Authors:  Peter Schmid-Grendelmeier; Frank Altznauer; Barbra Fischer; Christian Bizer; Alex Straumann; Günter Menz; Kurt Blaser; Brunello Wüthrich; Hans-Uwe Simon
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

9.  Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis.

Authors:  Richard J Noel; Philip E Putnam; Margaret H Collins; Amal H Assa'ad; Jesus R Guajardo; Sean C Jameson; Marc E Rothenberg
Journal:  Clin Gastroenterol Hepatol       Date:  2004-07       Impact factor: 11.382

10.  Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

Authors:  Vassili Soumelis; Pedro A Reche; Holger Kanzler; Wei Yuan; Gina Edward; Bernhart Homey; Michel Gilliet; Steve Ho; Svetlana Antonenko; Annti Lauerma; Kathleen Smith; Daniel Gorman; Sandra Zurawski; Jon Abrams; Satish Menon; Terri McClanahan; Rene de Waal-Malefyt Rd; Fernando Bazan; Robert A Kastelein; Yong-Jun Liu
Journal:  Nat Immunol       Date:  2002-06-10       Impact factor: 25.606

View more
  7 in total

1.  Elevated expression of activated TH2 cells and milk-specific TH2 cells in milk-induced eosinophilic esophagitis.

Authors:  Antonella Cianferoni; Melanie A Ruffner; Ryan Guzek; Shaobo Guan; Terri Brown-Whitehorn; Amanda Muir; Jonathan M Spergel
Journal:  Ann Allergy Asthma Immunol       Date:  2017-12-28       Impact factor: 6.347

Review 2.  Eosinophilic esophagitis: From pathophysiology to treatment.

Authors:  Alessandra D'Alessandro; Dario Esposito; Marcella Pesce; Rosario Cuomo; Giovanni Domenico De Palma; Giovanni Sarnelli
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

3.  Tacrolimus (FK506) treatment protects allergen-, IL-5- and IL-13-induced mucosal eosinophilia.

Authors:  Hemanth Kumar Kandikattu; Sathisha Upparahalli Venkateshaiah; Alok Kumar Verma; Anil Mishra
Journal:  Immunology       Date:  2021-02-28       Impact factor: 7.215

Review 4.  The rapidly changing world of food allergy in children.

Authors:  Katherine Anagnostou; Rosan Meyer; Adam Fox; Neil Shah
Journal:  F1000Prime Rep       Date:  2015-03-03

5.  Noncanonical NF-κB signaling and the essential kinase NIK modulate crucial features associated with eosinophilic esophagitis pathogenesis.

Authors:  Kristin Eden; Daniel E Rothschild; Dylan K McDaniel; Bettina Heid; Irving C Allen
Journal:  Dis Model Mech       Date:  2017-12-19       Impact factor: 5.758

Review 6.  Tissue Remodeling in Chronic Eosinophilic Esophageal Inflammation: Parallels in Asthma and Therapeutic Perspectives.

Authors:  Quan M Nhu; Seema S Aceves
Journal:  Front Med (Lausanne)       Date:  2017-08-07

7.  Plasma Urea Cycle Metabolites May Be Useful Biomarkers in Children With Eosinophilic Esophagitis.

Authors:  Lindsay M Moye; Yuying Liu; Cristian Coarfa; Nagireddy Putluri; Jon Marc Rhoads
Journal:  Front Pediatr       Date:  2019-01-10       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.